2551
|
Laurent C, Charmpi K, Gravelle P, Tosolini M, Franchet C, Ysebaert L, Brousset P, Bidaut A, Ycart B, Fournié JJ. Several immune escape patterns in non-Hodgkin's lymphomas. Oncoimmunology 2015; 4:e1026530. [PMID: 26405585 PMCID: PMC4570141 DOI: 10.1080/2162402x.2015.1026530] [Citation(s) in RCA: 73] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2015] [Revised: 02/27/2015] [Accepted: 02/27/2015] [Indexed: 12/31/2022] Open
Abstract
Follicular Lymphomas (FL) and diffuse large B cell lymphomas (DLBCL) must evolve some immune escape strategy to develop from lymphoid organs, but their immune evasion pathways remain poorly characterized. We investigated this issue by transcriptome data mining and immunohistochemistry (IHC) of FL and DLBCL lymphoma biopsies. A set of genes involved in cancer immune-evasion pathways (Immune Escape Gene Set, IEGS) was defined and the distribution of the expression levels of these genes was compared in FL, DLBCL and normal B cell transcriptomes downloaded from the GEO database. The whole IEGS was significantly upregulated in all the lymphoma samples but not in B cells or other control tissues, as shown by the overexpression of the PD-1, PD-L1, PD-L2 and LAG3 genes. Tissue microarray immunostainings for PD-1, PD-L1, PD-L2 and LAG3 proteins on additional biopsies from 27 FL and 27 DLBCL patients confirmed the expression of these proteins. The immune infiltrates were more abundant in FL than DLBCL samples, and the microenvironment of FL comprised higher rates of PD-1+ lymphocytes. Further, DLBCL tumor cells comprised a higher proportion of PD-1+, PD-L1+, PD-L2+ and LAG3+ lymphoma cells than the FL tumor cells, confirming that DLBCL mount immune escape strategies distinct from FL. In addition, some cases of DLBCL had tumor cells co-expressing both PD-1, PD-L1 and PD-L2. Among the DLBCLs, the activated B cell (ABC) subtype comprised more PD-L1+ and PD-L2+ lymphoma cells than the GC subtype. Thus, we infer that FL and DLBCL evolved several pathways of immune escape.
Collapse
Affiliation(s)
- Camille Laurent
- Institut Universitaire du Cancer-Oncopole de Toulouse ; Toulouse, France ; Centre de Recherches en Cancérologie de Toulouse; INSERM UMR1037 ; Toulouse, France ; Université Toulouse III Paul-Sabatier ; Toulouse, France ; ERL 5294 CNRS ; Toulouse, France ; Programme Hospitalo-Universitaire en Cancérologie CAPTOR ; Toulouse, France ; Institut Carnot Lymphome CALYM ; Toulouse, France ; Laboratoire d'Excellence 'TOUCAN' ; Toulouse, France
| | - Konstantina Charmpi
- Laboratoire d'Excellence 'TOUCAN' ; Toulouse, France ; Laboratoire Jean Kuntzmann; CNRS UMR5224 ; Grenoble, France
| | - Pauline Gravelle
- Institut Universitaire du Cancer-Oncopole de Toulouse ; Toulouse, France ; Centre de Recherches en Cancérologie de Toulouse; INSERM UMR1037 ; Toulouse, France ; Université Toulouse III Paul-Sabatier ; Toulouse, France ; ERL 5294 CNRS ; Toulouse, France ; Programme Hospitalo-Universitaire en Cancérologie CAPTOR ; Toulouse, France ; Institut Carnot Lymphome CALYM ; Toulouse, France ; Laboratoire d'Excellence 'TOUCAN' ; Toulouse, France
| | - Marie Tosolini
- Centre de Recherches en Cancérologie de Toulouse; INSERM UMR1037 ; Toulouse, France ; Université Toulouse III Paul-Sabatier ; Toulouse, France ; ERL 5294 CNRS ; Toulouse, France ; Programme Hospitalo-Universitaire en Cancérologie CAPTOR ; Toulouse, France ; Institut Carnot Lymphome CALYM ; Toulouse, France ; Laboratoire d'Excellence 'TOUCAN' ; Toulouse, France
| | - Camille Franchet
- Institut Universitaire du Cancer-Oncopole de Toulouse ; Toulouse, France
| | - Loïc Ysebaert
- Institut Universitaire du Cancer-Oncopole de Toulouse ; Toulouse, France ; Centre de Recherches en Cancérologie de Toulouse; INSERM UMR1037 ; Toulouse, France ; Université Toulouse III Paul-Sabatier ; Toulouse, France ; ERL 5294 CNRS ; Toulouse, France ; Programme Hospitalo-Universitaire en Cancérologie CAPTOR ; Toulouse, France ; Institut Carnot Lymphome CALYM ; Toulouse, France ; Laboratoire d'Excellence 'TOUCAN' ; Toulouse, France
| | - Pierre Brousset
- Institut Universitaire du Cancer-Oncopole de Toulouse ; Toulouse, France ; Centre de Recherches en Cancérologie de Toulouse; INSERM UMR1037 ; Toulouse, France ; Université Toulouse III Paul-Sabatier ; Toulouse, France ; ERL 5294 CNRS ; Toulouse, France ; Programme Hospitalo-Universitaire en Cancérologie CAPTOR ; Toulouse, France ; Institut Carnot Lymphome CALYM ; Toulouse, France ; Laboratoire d'Excellence 'TOUCAN' ; Toulouse, France
| | | | - Bernard Ycart
- Laboratoire d'Excellence 'TOUCAN' ; Toulouse, France ; Laboratoire Jean Kuntzmann; CNRS UMR5224 ; Grenoble, France
| | - Jean-Jacques Fournié
- Centre de Recherches en Cancérologie de Toulouse; INSERM UMR1037 ; Toulouse, France ; Université Toulouse III Paul-Sabatier ; Toulouse, France ; ERL 5294 CNRS ; Toulouse, France ; Programme Hospitalo-Universitaire en Cancérologie CAPTOR ; Toulouse, France ; Institut Carnot Lymphome CALYM ; Toulouse, France ; Laboratoire d'Excellence 'TOUCAN' ; Toulouse, France
| |
Collapse
|
2552
|
Biomarkers for glioma immunotherapy: the next generation. J Neurooncol 2015; 123:359-72. [PMID: 25724916 DOI: 10.1007/s11060-015-1746-9] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2014] [Accepted: 02/16/2015] [Indexed: 12/11/2022]
Abstract
The term "biomarker" historically refers to a single parameter, such as the expression level of a gene or a radiographic pattern, used to indicate a broader biological state. Molecular indicators have been applied to several aspects of cancer therapy: to describe the genotypic and phenotypic state of neoplastic tissue for prognosis, to predict susceptibility to anti-proliferative agents, to validate the presence of specific drug targets, and to evaluate responsiveness to therapy. For glioblastoma (GBM), immunohistochemical and radiographic biomarkers accessible to the clinical lab have informed traditional regimens, but while immunotherapies have emerged as potentially disruptive weapons against this diffusely infiltrating, heterogeneous tumor, biomarkers with strong predictive power have not been fully established. The cancer immunotherapy field, through the recently accelerated expansion of trials, is currently leveraging this wealth of clinical and biological data to define and revise the use of biomarkers for improving prognostic accuracy, personalization of therapy, and evaluation of responses across the wide variety of tumors. Technological advancements in DNA sequencing, cytometry, and microscopy have facilitated the exploration of more integrated, high-dimensional profiling of the disease system-incorporating both immune and tumor parameters-rather than single metrics, as biomarkers for therapeutic sensitivity. Here we discuss the utility of traditional GBM biomarkers in immunotherapy and how the impending transformation of the biomarker paradigm-from single markers to integrated profiles-may offer the key to bringing predictive, personalized immunotherapy to GBM patients.
Collapse
|
2554
|
Perales Palacios I, García Campos F, Michaus Oquiñena L, Blanco Guzmán S, Lantero Benedito M. [Isolation of Plesiomonas shigelloides in a case of gastroenteritis]. Rev Clin Esp 1984; 15:353-365. [PMID: 6658089 DOI: 10.1038/s41571-018-0002-6] [Citation(s) in RCA: 309] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|